Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.

Introduction: Extensive Plasmodium falciparum genetic diversity plays a role in immune evasion, and antibody responses can be strain-specific or broadly reactive depending on the epitope. Controlled human malaria infection (CHMI) allows investigation of immune responses to variant parasite proteins after a single infection with a known strain. Methods: We designed a novel diversity-reflecting peptide microarray containing 638,817 unique peptides representing 22,655 variants of 227 proteins from 23 P. falciparum genome assemblies and 379 field isolates. Using this array, we probed sera from 38 malaria naïve adults before and 28 days after CHMI with one of two genetically distinct P. falciparum strains, NF54 (n = 21) or 7G8 (n = 17). We examined fold-increase in antibody response (intensity) and cross-reactivity to protein variants (breadth). ABCPred was used to predict linear epitopes for all 227 proteins. We used MEME to identify enriched motifs in regions of high intensity or breadth, which were presumed to be potential epitopes. Results: While the two CHMI groups had similar intensity of responses to all proteins on the array, 20 proteins on the array had differential breadth of responses and participants infected with 7G8 strain had a higher breadth of responses to 17 of them. Of 543 ABCPred-predicted epitopes, 66 overlapped with MEME-identified epitopes, six of which were highly cross-reactive with >95% of peptide variants serorecognized by at least one CHMI group. Discussion: Overall, we found most antibody responses to be comparable after infection with the NF54 strain or 7G8 strain, but we saw notable differences for ~10% of proteins on the array. While many MEME-identified epitopes from highly cross-reactive proteins were asparagine rich, an epitope from PF3D7_1033200 (ETRAMP10.2) was not. Highly cross-reactive responses to ETRAMP10.2 could be further characterized and ETRAMP10.2 could be considered for inclusion in a next generation vaccine.